Trevi Therapeutics to Participate in Upcoming Events

Trevi Therapeutics (Nasdaq: TRVI) announced senior management will participate in investor events and an Investor & Analyst Day in April–May 2026.

Rhea-AI Impact

(Neutral)

Rhea-AI Sentiment

(Positive)

Rhea-AI Summary

Trevi Therapeutics (Nasdaq: TRVI) announced senior management will participate in investor events and an Investor & Analyst Day in April–May 2026. Key appearances include Needham Virtual Healthcare Conference (fireside chat April 13), Raymond James Biotech Symposium (April 14), Oppenheimer Innovation on the Island (April 27–29), and an in-person Analyst Day May 7, 2026 in Midtown New York.

Management attendees include Jennifer Good, President and CEO, and David Hastings, CFO; the Analyst Day will feature key opinion leaders in chronic cough in IPF/ILD and RCC and a virtual webcast option.

Argus Apr 1 session

-2.93% close to close Open Argus

Details

News Market Reaction – TRVI

On Apr 1, the day this news came out, TRVI closed 2.93% below the previous close.

Data tracked by StockTitan Argus for the Apr 1 session.

Market Context

This announcement details Trevi’s participation in several April events and a May 7 Investor and Ana...

Analysis

This announcement details Trevi’s participation in several April events and a May 7 Investor and Analyst Day from 10:00 a.m. to 12:00 p.m. ET, featuring senior management and key opinion leaders in IPF/ILD and refractory chronic cough. It builds on recent disclosures of FDA alignment for Phase 3 programs and cash runway into 2028. Investors may watch for further detail on Haduvio’s development plans, trial timing, and strategic priorities communicated through these scheduled appearances.

Key Figures

Needham conference dates: April 13–16, 2026 Needham fireside time: 12:45 p.m. ET Raymond James date: April 14, 2026 +3 more

Needham conference dates: April 13–16, 2026; 25th Annual Needham Virtual Healthcare Conference
Needham fireside time: 12:45 p.m. ET; April 13 fireside chat
Raymond James date: April 14, 2026; Raymond James 2026 Biotech Innovation Symposium
Oppenheimer dates: April 27–29, 2026; Oppenheimer’s 2026 Innovation on the Island
Investor Day date: May 7, 2026; Trevi Investor and Analyst Day in New York
Investor Day time: 10:00 a.m. to 12:00 p.m. ET; Trevi Investor and Analyst Day session window

Historical Context

5 past events · Latest: Mar 17

5 events

Mar 17
Earnings and pipeline

24h Move

-4.5%

Year-end 2025 results and Phase 3/2b development plans with long cash runway.
Mar 10
Earnings call date

24h Move

+1.5%

Announcement of March 17 earnings call and webcast registration details.
Mar 09
Clinical FDA alignment

24h Move

-12.0%

End-of-Phase 2 FDA alignment and plan for two pivotal Phase 3 trials.
Mar 02
Conference participation

24h Move

+5.5%

Participation in March 2026 healthcare and rare disease conferences.
Feb 17
Conference participation

24h Move

-2.4%

Oppenheimer healthcare conference fireside chat and investor meetings.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

idiopathic pulmonary fibrosis, interstitial lung disease, refractory chronic cough

3 terms

idiopathic pulmonary fibrosis medical

"chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF"

Idiopathic pulmonary fibrosis is a chronic lung disease in which the air‑carrying tissue becomes progressively thickened and scarred for no identifiable reason, making the lungs stiff and less able to move oxygen—similar to a sponge that hardens and loses its pores. It matters to investors because it is life‑limiting with limited effective treatments, so clinical trial outcomes, regulatory approvals, pricing and reimbursement decisions can strongly affect the commercial value of therapies and the financial prospects of companies developing treatments.

interstitial lung disease medical

"idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD)"

A group of lung conditions that cause inflammation and scarring of the thin tissue between the air sacs, which makes it harder for oxygen to pass into the blood; imagine the lungs’ fine filters becoming stiff and less effective. Investors care because reports of interstitial lung disease can affect a drug’s safety profile, trigger regulatory warnings or label changes, and shift demand for treatments or create liability risks that influence a company’s valuation.

refractory chronic cough medical

"non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC)"

A refractory chronic cough is a long-lasting cough that persists despite standard medical evaluation and treatment, typically lasting eight weeks or more and not improving with usual therapies. Investors should care because it represents a clear unmet medical need that can drive demand for new drugs, devices, or diagnostics—similar to a stubborn problem customers keep returning to a store for until a better solution appears—affecting market potential and regulatory attention.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

04/01/2026 - 07:30 AM

NEW HAVEN, Conn., April 01, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will be participating in the following events.

25^th Annual Needham Virtual Healthcare Conference
April 13 – 16, 2026, Virtual
Fireside Chat: April 13, 12:45 p.m. ET
Trevi Representatives: Jennifer Good, President and CEO, and David Hastings, CFO

Raymond James 2026 Biotech Innovation Symposium
April 14, 2026, New York, New York
Trevi Representatives: Jennifer Good, President and CEO, and David Hastings, CFO

Oppenheimer’s 2026 Innovation on the Island
April 27 – 29, 2026, Puerto Rico
Trevi Representative: Jennifer Good, President and CEO

Trevi Therapeutics Investor and Analyst Day
May 7, 2026, Midtown New York, New York
10:00 a.m. to 12:00 p.m. ET
Representatives: Trevi senior management will be joined by key opinion leaders in chronic cough in IPF/ILD and RCC
To register for the in-person event or virtual webcast, click here. 

About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). Haduvio is the first and only investigational therapy to show a statistically-significant reduction in cough frequency in clinical trials across both patients with IPF-related chronic cough and in patients with RCC. Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors that play a key role in controlling chronic cough. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency.

Chronic cough in patients with IPF and non-IPF ILD is a condition with high unmet need and no FDA-approved therapies. There are ~150,000 U.S. patients with IPF, and two-thirds of these patients are faced with uncontrolled chronic cough. Additionally, there are ~228,000 U.S. patients with non-IPF ILD, with 50-60% having uncontrolled chronic cough. The impact of chronic cough is significant, with patients coughing up to 1,500 times per day. This consistent cough, and any associated damage, may lead to a higher risk of morbidity and mortality, including worsening disease, a higher risk of progression, increased respiratory hospitalizations, and a decline in patients' quality of life.

RCC is a condition with high unmet need and no FDA-approved therapies. RCC is defined as a persistent cough lasting >8 weeks despite treatment for an underlying condition (i.e., asthma, gastroesophageal reflux disease, non-asthmatic eosinophilic bronchitis, upper airway cough syndrome, or post-nasal drip) and includes unexplained chronic cough. There are ~2-3 million U.S. patients with RCC, and it is believed to be associated with cough reflex hypersensitivity involving both the central and peripheral nervous systems. RCC is highly debilitating and may impact patients physically, psychologically, and socially.

Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority.

For more information, visit www.TreviTherapeutics.com and follow Trevi on X (formerly Twitter) and LinkedIn.

Investor Contact
Jonathan Carlson
Trevi Therapeutics, Inc.
(203) 654 3286
IR@trevitx.com

Media Contact
Rosalia Scampoli
914-815-1465
rscampoli@marketcompr.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Trevi Therapeutics (TRVI) hold its Investor and Analyst Day in 2026?

Trevi will hold its Investor and Analyst Day on May 7, 2026 in Midtown New York. According to the company, the event runs 10:00 a.m. to 12:00 p.m. ET and includes senior management and key opinion leaders in chronic cough.

Who from Trevi Therapeutics (TRVI) will speak at the Needham Virtual Healthcare Conference April 13, 2026?

Jennifer Good, President and CEO, and David Hastings, CFO, will participate in the Needham fireside chat April 13. According to the company, the session is scheduled for 12:45 p.m. ET during the April 13–16 virtual conference.

How can investors access Trevi Therapeutics (TRVI) presentations at the April 2026 events?

Investors can attend some events in person and others virtually; a webcast option is available for the Analyst Day. According to the company, registration information and a virtual webcast link are provided for the in-person and online sessions.

Which events will Trevi Therapeutics (TRVI) attend in mid to late April 2026?

Trevi will attend Raymond James Biotech Innovation Symposium on April 14, 2026 in New York and Oppenheimer Innovation on the Island April 27–29, 2026 in Puerto Rico. According to the company, Jennifer Good and David Hastings will represent Trevi at these events.

Will Trevi Therapeutics (TRVI) include clinical experts at its May 7, 2026 Analyst Day?

Yes, Trevi will include key opinion leaders in chronic cough for IPF/ILD and RCC at the May 7 Analyst Day. According to the company, senior management will be joined by clinical experts to discuss the program and clinical context.

Trevi Therapeutics to Participate in Upcoming Events

Rhea-AI Summary

Positive